Skip to main
BNGO
BNGO logo

Bionano Genomics (BNGO) Stock Forecast & Price Target

Bionano Genomics (BNGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bionano Genomics demonstrated strong sales growth in its nanochannel array flowcells, with a notable 17% increase from 6,165 units sold in 2Q24 to 7,233 units in 2Q25, and a 7% increase from 7,835 units in 3Q24 to 8,390 units in 3Q25. The company's revenue from consumables and software also improved, rising by 16% year-over-year in 2Q25, leading to an overall 11% increase in combined revenue after adjusting for discontinued services. Additionally, Bionano's installation expectations for the OGM system are projected to rise to 20-25 units for FY2025, up from 15-20, indicating positive momentum in both existing and new markets, notably in Japan.

Bears say

Bionano Genomics faces significant risks that contribute to a negative outlook for its stock, including lower than projected market uptake of its products and reduced utilization of existing systems. Additionally, the company's ability to secure further capital for operations is uncertain, which raises concerns regarding its financial stability and potential dilution risks for shareholders. These factors, combined with a conservative EV/Revenue multiple of 1.2x, suggest that the company may struggle to achieve its projected sales and maintain its current valuation metrics.

Bionano Genomics (BNGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bionano Genomics (BNGO) Forecast

Analysts have given Bionano Genomics (BNGO) a Buy based on their latest research and market trends.

According to 3 analysts, Bionano Genomics (BNGO) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bionano Genomics (BNGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.